Posted by Michael Wonder on 01 Nov 2016
Head and neck cancer drug is not cost-effective
1 November 2016 - Cetuximab is not value for money says NICE in new draft guidance.
NICE does not recommend head and neck cancer drug cetuximab in draft guidance out for consultation.
In 2009 when NICE originally looked at cetuximab it found it was not cost effective, and it was later made available through the Cancer Drugs Fund.
NICE has looked again at cetuximab as part of its programme to appraise drugs that are currently available on the CDF and found that despite new evidence and a drop in price it was still not cost effective.
